EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes

Lan Chen iD, Xi Yan, Ting Luo iD, Tinglun Tian, Ping He, Xiaorong Zhong

Cancer Medicine · 2024-05 · 13 (10)

DOI: 10.1002/cam4.7295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.05.2024. Verfasst von Lan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China. Hauptthemen laut MEDLINE: Ketones, Furans, Breast Neoplasms, Anthracyclines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This prospective real‐world study aimed to assess the efficacy and safety of eribulin in the clinical practice against advanced breast cancer (ABC) in China. Patients and Methods In this study, eligible patients with inoperable locally advanced or metastatic breast cancer who had experienced prior neo−/adjuvant or failed the palliative treatment with anthracycline/taxanes were included. Eribulin (1.4 mg/m 2 ) was infused intravenously on Day 1 and Day 8 every 3 weeks until disease progression or intolerable toxicity occurred. The progression‐free survival (PFS), overall response rate (ORR), disease control rate (DCR), and safety of the treatment were assessed.

Results

One hundred and thirty‐four patients were enrolled. The median PFS (mPFS) was 4.3 months (95% CI: 0.3–15.4). The ORR and DCR was 32.1% and 79.1%, respectively. The mPFS of patients who received eribulin as first‐ or second‐line treatment was significantly better than those who received eribulin as ≥3‐line treatment (6.9 months [95% CI: 3.2–8.8] vs. 4.0 months [95% CI: 3.4–4.6], p = 0.006). The mPFS of patients with triple‐negative, HER2‐positive, and HER2(−)/HR(+) was 3.4 (95% CI: 2.7–4.1), 6.2 (95% CI: 2.3–10.1) and 5.0 months (95% CI: 4.1–5.9), respectively. HER2(+) patients had significantly longer PFS than TNBC patients ( p = 0.022). Patients received combination therapy had a significantly longer mPFS than those who received eribulin monotherapy (5.0 months [95% CI 3.6–6.3] vs. 4.0 months [95% CI: 3.3–4.7] [ p = 0.016]). Multivariate analysis revealed that MBC patients with a molecular typing of non‐TNBC receiving eribulin as ≤2‐line therapy and combination therapy had a low risk of disease progression. Neutropenia (33.58%), leukopenia (11.94%), and thrombocytopenia (4.48%) were the most common treatment‐related adverse events.

Conclusion

Eribulin demonstrated effective clinical activity and a favorable tolerability profile in Chinese patients with ABC in the real‐world. The efficacy and safety profile were consistent with those reported in previous randomized phase 3 trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetonesFuransBreast NeoplasmsAnthracyclinesHumansFemaleMiddle AgedAdultAgedProspective StudiesTaxoidsProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeNeoplasm MetastasisAntineoplastic AgentsChinaPolyether Polyketides

Stichwörter der Autor:innen

advanced breast cancereribulin mesylateobservation studysafetytoxicity

Substanzen

KetonesFuranseribulinAnthracyclinesTaxoidsAntineoplastic AgentsPolyether Polyketides

Autor:innen und Institutionen

  • Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
  • Department of Medical Oncology, Head and Neck Cancer Department, West China Hospital, Chengdu, Sichuan Province, People's Republic of China.

ORCID-Profile: Lan Chen, Ting Luo

Zitieren

APA

Chen, L., Yan, X., Luo, T., Tian, T., He, P., & Zhong, X. (2024). Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes. Cancer Medicine, 13(10). https://doi.org/10.1002/cam4.7295

Vancouver

Chen L, Yan X, Luo T, Tian T, He P, Zhong X. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes. Cancer Medicine. 2024;13(10). doi:10.1002/cam4.7295

BibTeX
@article{Chen2024,
  author = {Chen, Lan and Yan, Xi and Luo, Ting and Tian, Tinglun and He, Ping and Zhong, Xiaorong},
  title = {Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {10},
  doi = {10.1002/cam4.7295}
}
Kostenlos starten →